All In Biotech

Drug Trial Radar · NCT05434156

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

A Phase I, Randomised, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Intravenous Doses of ELE-101 in Healthy Adult Participants (Part 1) and Part 2, Open-Label Study to Evaluate a Range of Pharmacodynamic Effects of a Single Intravenous Dose of ELE-101 in Patients With Major Depressive Disorder.

Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Oct 27, 2022

Primary completion

Dec 2025

Study completion Mar 2026

Sponsor

Lead sponsor
Eleusis TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Beckley Psytech Limited
First posted
Jun 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).

Conditions

  • Healthy Volunteers
  • Major Depressive Disorder
  • Depression

Interventions

  • ELE-101Drug

    ELE-101 solution for intravenous infusion

  • ELE-101 PlaceboDrug

    ELE-101 placebo matching solution for intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Percentage of participants with at least one safety eventTime frame: Baseline up to Day 8
  2. Part 2: Subjective Drug Intensity RatingsTime frame: pre-dose and at multiple time-points up to 24 hours post-dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • MAC Clinical Research

    Liverpool, United Kingdom

  • MAC Clinical Research

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.